David N Adam1,2,3, Marie Y Jablonski Bernasconi4, Henrik Thoning4, Jashin J Wu5. 1. Division of Dermatology, Temerty Department of Medicine, University of Toronto, Toronto, ON, Canada. dnadam@gmail.com. 2. CCA Medical Research, Ajax, ON, Canada. dnadam@gmail.com. 3. Probity Medical Research, Waterloo, ON, Canada. dnadam@gmail.com. 4. Leo Pharma, Ballerup, Denmark. 5. Department of Dermatology, University of Miami Miller School of Medicine, Miami, FL, USA.
Abstract
INTRODUCTION: To date, there have been no head-to-head clinical studies comparing calcipotriol 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam and halobetasol propionate 0.01% plus tazarotene 0.045% (HP/Taz) lotion for the treatment of plaque psoriasis. However, the efficacy of 4 weeks of Cal/BD foam and 8 weeks of HP/Taz lotion has been compared using a matching-adjusted indirect comparison (MAIC) approach. Here, we compare the efficacy and safety of Cal/BD foam and HP/Taz lotion for up to 52 weeks. METHODS: An unanchored MAIC was conducted using individual patient data from the PSO-LONG Cal/BD foam trial and a 52-week, open-label phase 3 study of HP/Taz lotion (NCT02462083). Key outcomes of interest were Physician's Global Assessment (PGA) success (PGA 0/1 with ≥ 2-point improvement) after 4 or 8 weeks of open-label therapy; the proportion of patients who had body surface area affected (BSA) ≤ 3 after open-label therapy who maintained BSA ≤ 3 to week 52; and adverse events (AEs). RESULTS: After matching, patients were statistically significantly more likely to have PGA success after 4 weeks of Cal/BD foam than after 8 weeks of HP/Taz lotion (84.5% versus 54.4%; p < 0.01). At week 52, 92.5% and 92.4% of patients receiving proactive and reactive Cal/BD foam, respectively, maintained BSA ≤ 3, compared with 49.3% of those treated with HP/Taz lotion (both p < 0.01). Treatment-related AEs, AEs leading to withdrawal, and AEs associated with drug application (dermatitis, application site pain, and pruritus) were significantly rarer with Cal/BD foam than with HP/Taz lotion (all p < 0.01). CONCLUSIONS: Cal/BD aerosol foam demonstrated significantly greater efficacy than HP/Taz lotion, and had a more favorable safety profile, compared with HP/Taz lotion, for up to 52 weeks. Proactive Cal/BD foam maintenance therapy and reactive use of Cal/BD foam following relapse both had significant advantages over HP/Taz lotion.
INTRODUCTION: To date, there have been no head-to-head clinical studies comparing calcipotriol 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam and halobetasol propionate 0.01% plus tazarotene 0.045% (HP/Taz) lotion for the treatment of plaque psoriasis. However, the efficacy of 4 weeks of Cal/BD foam and 8 weeks of HP/Taz lotion has been compared using a matching-adjusted indirect comparison (MAIC) approach. Here, we compare the efficacy and safety of Cal/BD foam and HP/Taz lotion for up to 52 weeks. METHODS: An unanchored MAIC was conducted using individual patient data from the PSO-LONG Cal/BD foam trial and a 52-week, open-label phase 3 study of HP/Taz lotion (NCT02462083). Key outcomes of interest were Physician's Global Assessment (PGA) success (PGA 0/1 with ≥ 2-point improvement) after 4 or 8 weeks of open-label therapy; the proportion of patients who had body surface area affected (BSA) ≤ 3 after open-label therapy who maintained BSA ≤ 3 to week 52; and adverse events (AEs). RESULTS: After matching, patients were statistically significantly more likely to have PGA success after 4 weeks of Cal/BD foam than after 8 weeks of HP/Taz lotion (84.5% versus 54.4%; p < 0.01). At week 52, 92.5% and 92.4% of patients receiving proactive and reactive Cal/BD foam, respectively, maintained BSA ≤ 3, compared with 49.3% of those treated with HP/Taz lotion (both p < 0.01). Treatment-related AEs, AEs leading to withdrawal, and AEs associated with drug application (dermatitis, application site pain, and pruritus) were significantly rarer with Cal/BD foam than with HP/Taz lotion (all p < 0.01). CONCLUSIONS: Cal/BD aerosol foam demonstrated significantly greater efficacy than HP/Taz lotion, and had a more favorable safety profile, compared with HP/Taz lotion, for up to 52 weeks. Proactive Cal/BD foam maintenance therapy and reactive use of Cal/BD foam following relapse both had significant advantages over HP/Taz lotion.
Authors: James E Signorovitch; Eric Q Wu; Andrew P Yu; Charles M Gerrits; Evan Kantor; Yanjun Bao; Shiraz R Gupta; Parvez M Mulani Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: Mark Lebwohl; Leon Kircik; Jean-Philippe Lacour; Monika Liljedahl; Charles Lynde; Marie Holst Mørch; Kim A Papp; Jean-Luc Perrot; Linda Stein Gold; Amrit Takhar; Diamant Thaçi; Richard B Warren; Andreas Wollenberg Journal: J Am Acad Dermatol Date: 2020-09-18 Impact factor: 11.527
Authors: Alan Menter; Alice Gottlieb; Steven R Feldman; Abby S Van Voorhees; Craig L Leonardi; Kenneth B Gordon; Mark Lebwohl; John Y M Koo; Craig A Elmets; Neil J Korman; Karl R Beutner; Reva Bhushan Journal: J Am Acad Dermatol Date: 2008-05 Impact factor: 11.527
Authors: Linda Stein Gold; Mark G Lebwohl; Jeffrey L Sugarman; David M Pariser; Tina Lin; Gina Martin; Radhakrishnan Pillai; Robert Israel; Tage Ramakrishna Journal: J Am Acad Dermatol Date: 2018-04-01 Impact factor: 11.527
Authors: M G Lebwohl; L Stein Gold; K Papp; G Han; D M Pariser; T Lin; S Harris; A Jacobson Journal: J Eur Acad Dermatol Venereol Date: 2021-02-07 Impact factor: 6.166
Authors: David M Phillippo; Anthony E Ades; Sofia Dias; Stephen Palmer; Keith R Abrams; Nicky J Welton Journal: Med Decis Making Date: 2017-08-19 Impact factor: 2.583
Authors: A P Bewley; N H Shear; P G Calzavara-Pinton; J B Hansen; M E Nyeland; J Signorovitch Journal: J Eur Acad Dermatol Venereol Date: 2019-03-19 Impact factor: 6.166
Authors: John Koo; Stephen Tyring; William P Werschler; Suzanne Bruce; Martin Olesen; John Villumsen; Jerry Bagel Journal: J Dermatolog Treat Date: 2015-10-07 Impact factor: 3.359